ArticleJournal of occupational medicine and toxicology (London, England)2026
The ability of the GENESIS-UV metric to reflect the positive dose-response relationship between cumulative occupational UV exposure and squamous cell carcinoma of the skin.
Article in Journal of occupational medicine and toxicology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe newly developed GENESIS-UV metric is based on occupational UV exposure measurements in about 1,000 outdoor-workers (covering 250 different occupational settings). The GENESIS-UV metric calculates occupational exposure values for the standard erythema dose (SED) that differ substantially from those produced by the “Wittlich metric” which applies multiple correction factors to a fixed SED reference value of 300 SED per year. This Wittlich metric has served as the basis for calculating occupational UV exposure of occupational disease No. 5103 (“squamous cell carcinoma or multiple actinic keratoses caused by natural UV radiation”) in Germany since 2015. In a large case-control study (“FB181”, 632 cases and 632 individually matched control subjects), a positive dose-response relationship between UV exposure estimated using the “Wittlich metric” and squamous cell carcinoma (SCC) of the skin could be derived. This study aimed to investigate whether the increased SCC risk for high occupational UV exposure found in the FB181 study can be reflected with the new GENESIS-UV metric.
methodsBased on propensity-score matched data from the FB181 study, odds ratios (OR) with 95% confidence intervals (CI) for categorized occupational UV exposure were calculated using conditional logistic regression analysis. The analyses were adjusted for age, sex, skin phototype, and non-occupational UV exposure. To examine the suitability of the GENESIS-UV metric, exposure was calculated using both the Wittlich metric and the GENESIS-UV metric. The goodness of fit was assessed using the Akaike information criterion (AIC).
resultsWhen applying the Wittlich metric, individuals with high cumulative occupational UV exposure (≥ 90th percentile) show a statistically significant increase in OR of 1.95 (95% CI 1.19–3.18). When applying the GENESIS-UV metric, the corresponding OR for reaching or exceeding the 90th percentile is 2.23 (95% CI 1.36–3.65). The goodness of fit of the GENESIS-UV metric is substantially better than that of the Wittlich metric (AIC of 748.0 versus 758.6).
conclusionsApplying the newly developed GENESIS-UV metric, we were able to confirm the positive dose-response relationship between occupational UV exposure and squamous cell carcinoma of the skin in this sensitivity analysis of the FB181 case-control study. The GENESIS-UV metric proves to be suitable for determining occupational UV exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.